

BENCHMARKS
Nifty 18,338.55 176.8

NSE GAINER-LARGE CAP
IRCTC 5,463.55 534.75

FEATURED FUNDS ★★★★★ 5Y RETURN
ICICI Prudential Midcap ... 17.64% INVEST NOW

MARKET WATCH ▾

THE ECONOMIC TIMES | Industry

English Edition | E-Paper

Subscribe Sign In

Special Offer on ET Prime

Home ETPrime Markets News **Industry** RISE Politics Wealth MF Tech Jobs Opinion NRI Panache ET NOW More ▾

Auto ▾ Banking/Finance ▾ Cons. Products ▾ Energy ▾ Renewables ▾ Ind'l Goods/Svs ▾ **Healthcare/Biotech** ▾ Services ▾ Media/Entertainment ▾ More ▾

Business News > Industry > Healthcare/Biotech > Pharmaceuticals > Delhi High Court favours Natco, Alembic; allows them to export generics of Bayer's drugs

Delhi High Court favours Natco, Alembic; allows them to export generics of Bayer's drugs

ET Bureau Last Updated: Mar 08, 2017, 02:29 PM IST

SHARE FONT SIZE SAVE PRINT COMMENT

Synopsis

Bayer had approached court in 2016 to stop Alembic Pharmaceuticals from exporting its generic of the German company's blood thinner brand 'Xarelto' (Rivaroxaban), used to prevent and treat dangerous blood clots.



ET Bureau

NEW DELHI: The **Delhi High Court** has ruled that Indian companies Alembic and **Natco** **NSE -0.48%** Pharmaceuticals can export generic versions of two of German drug maker **Bayer** **NSE 0.88%**'s life saving medicines for research and regulatory pu

Alembic Pharma
806.60 **-9.45 (-1.16%)**

TOP INSIGHT ▶
Intraday fact check
In the last 10 years, only 1.65% trading sessions saw intraday declines higher than 5%
See More






Indian makers of generic drugs embroiled inventors.

Bayer had approached court in 2016 to stop **Alembic Pharmaceuticals** **NSE -1.16%** from exporting its generic of the German company's blood thinner brand 'Xarelto' (Rivaroxaban), used to prevent and treat dangerous blood clots.

The company also sued the government in 2014 to stop Natco's export of '**Sorafenat**', the Indian company's generic brand of Bayer's cancer drug 'Nexavar' (**Sorafenib**) used to treat three types of cancers. Natco was granted a compulsory licence to manufacture the generic of Nexavar in 2012--a decision that the Supreme Court in 2014 when Bayer appealed the move and asked for the com to be set aside.

Nifty **CLOSED**
18338.55 176

Popular in Industry

1. Ratan Tata credits Chandra for decision behind Air India buy 
2. Vodafone, Aditya Birla Group may invest \$400 million into Vodafone Idea 
3. Govt asks power plants to blend 10% imported coal to step up supply 
4. Five banks may bid for Citi's India consumer businesses 
5. Tata Sons shortlists candidates for Air India CEO post 

(Ad) bptp.com

2, 3, 4 & 5 BHK Homes starting 85L*



VISIT SITE

Sponsored by

In a setback to the German drug giant, the court has ruled in favour of the Indian companies, allowing them to continue with the exports for clinical development and regulatory purposes.

"I've held their exports to be permissible," stated Justice Rajiv Sahai Endlaw while pronouncing the judgment.

Alembic and Natco are required to give an undertaking that they will not export their drugs for any other purpose than those in Section 107A of the Indian Patents Act, 1970.

Section 107A includes acts that would not be considered an infringement of a company's patent rights. Under this provision, companies can make, use, sell and import a patented invention solely for purposes reasonably related to the development and submission of information required under any law in force in India or another country.

According to Bayer, Alembic was infringing its patent on the blood thinner by exporting and dealing in the drug, Rivaroxaban. Alembic had argued that exporting its version of the drug was well within the provisions of Section 107A. Bayer, however, claimed that Alembic had exported 90 kgs of the drug worth Rs3 crore and that the export of such a large quantity was not as per this section.





In Natco's case, Bayer took objection to the Indian company's export of Sorafenat and said that compulsory licence conditions clearly stipulate that the licence has been granted for the sale of the drug within Indian territory.

Natco sought permission from the court to send samples of the active

TOP TRENDING INDUSTRY TERMS

- Tata Power
- Vodafone Idea
- Ratan Tata
- Bharat Biotech

Most Popular News

- 4th richest Indian shrugs off ESG rules to own one-third in a cigarette firm 
- Rakesh Jhunjhunwala's latest pick is a three-bagger of last one year 
- Is Bitcoin headed towards record high? Explained in 4 charts 
- One of India's biggest technology recruiters is giving the campus a skip 

NEXT STORY

Bharat Bio hopes to soon submit trial data for intranasal vaccine

Related Aspects c Alembic, told ET.

Nifty CLOSED 18338.55 176.80


erty Rights)," Pratibha Singh, counsel for

- GatiShakti: Breaking silos in logistics
- Growth history: Sifting through puzzles

By Teena Thacker, ET Bureau Last Updated: Oct 14, 2021, 07:15 AM IST

Synopsis

"The trials are ongoing, and we expect to submit data by the end of this year," a company insider said. The trials, including over 600 participants, are being conducted by dividing the volunteers into three groups.



Agencies

After receiving positive recommendations from the expert committee on **Covaxin** use for children, **Bharat Biotech** is now looking to submit the trial results of its **Covid-19 intranasal vaccine** by end of this year, people in the know told ET.

The first group is administered Covaxin as the first dose and intranasal vaccine as the second dose.

Nagesh Samant

BUY COAL INDIA FOR TARGET OF 350 RECORD DATE IS MARCH 2017 (RS) a company insider said. The trials, including over 600 participants, are being conducted by dividing the volunteers into three groups.

VIEW COMMENTS

ADD COMMENTS

The first group is administered Covaxin as the first dose and intranasal vaccine as the second dose. The second group will get both doses in the form of intranasal vaccine.

ETPrime stories of the day



The third group will get the intranasal vaccine as the first dose and Covaxin jab as the second dose. The doses are given 28 days apart. The intranasal vaccine can be game changer in the vaccination drive because it offers the convenience of administration.

The drug regulatory authority had in August given its approval to Hyderabad-based Bharat Biotech to conduct phase-2/3 trials on its intranasal vaccine.

The adenoviral intranasal vaccine BBV154 is the first of its kind **Covid-19** jab which has been undergoing human trials in India. The phase-1 trial in healthy volunteers of age group 18 to 60 years was well tolerated, the ministry of science and technology said in a statement earlier.

Nifty CLOSED 18338.55 176.80

It also said the vaccine was found to be safe, immunogenic and well-tolerated in the preclinical toxicity studies and was able to elicit high levels of

UPTO 70% OFF UPTO 40% OFF

1. Drug case live: No bail for Aryan Khan today order reserved for October 20
2. Ratan Tata credits Chaudhary for digital push behind Air India buy
3. The real problem with Aryan Khan's case is this
2. Vodafone, Aditya Birla Group may invest \$400 million into Vodafone Idea
3. Govt asks power plants to blend 10% imported coal to step up supply
4. Five banks may bid for Citi's India consumer businesses
5. Tata Sons shortlists candidates for Air India CEO post

TOP TRENDING INDUSTRY TERMS: Spicejet, India Railways, Punit Goenka, IMF

- Most Popular News
1. 4th richest Indian shrugs off ESG rules to own one-third in a cigarette firm

neutralizing antibodies in animal studies.

The development of Bharat Biotech's intranasal vaccine has been supported by the department of biotechnology (DBT) and Biotechnology Industry Research Assistance Council (BIRAC). The company strategised to fast-track research and development efforts, especially for vaccine development, diagnostics, drug repurposing, therapeutics and testing.

Bharat Biotech's Covaxin had demonstrated 77.8% efficacy against symptomatic Covid-19 and 93.4% against severe illness during the phase-3 clinical trials.

READ MORE NEWS ON

[Bharat Biotech](#) [Covaxin](#) [Trial Data](#) [Intranasal Vaccine](#) [Coronavirus Cases](#)

(Catch all the **Business News**, **Breaking News** Events and **Latest News** Updates on **The Economic Times**.)

Download **The Economic Times News App** to get Daily Market Updates & Live Business News.

ETPrime stories of the day



OMNICHANNEL

Jewellery on rent to virtual shopping: decoding Titan's post-pandemic digital playbook

7 mins read



INVESTING

Realty boom, capex cycle, Unitech's fall: what pro-cyclical investors can learn from the past

14 mins read



LOGISTICS

Why Rivigo, which hired from all sectors, is zeroing in on seasoned logistics hands for its revival

11 mins read

Subscribe to ETPrime



- 2. Rakesh Jhunjhunwala's latest pick is a three-bagger of last one year



- 3. Is Bitcoin headed towards record high? Explained in 4 charts



- 4. One of India's biggest technology recruiters is giving the campus a skip



Most Popular Opinion

- 1. Growth is gathering momentum, but...
- 2. GatiShakti: Breaking silos in logistics
- 3. Growth history: Sifting through puzzles

Top Category Deals



Instant 10% discount
Kitchen & Dining



200+ Deals
Major Appliances

Explore 20+ Categories >

Nifty **CLOSED**
18338.55 176.80

Latest News

1. Drug case live: No bail for Aryan Khan today, order reserved for October 20
2. Eye on Pakistan, Amit Shah recalls 2016 surgical strikes
3. The real problem with Aryan Khan's case is this



Search News, Stock Quotes & NAV

BROWSE COMPANIES:

- A
 - B
 - C
 - D
 - E
 - F
 - G
 - H
 - I
 - J
 - K
 - L
 - M
 - N
 - O
 - P
 - Q
 - R
 - S
 - T
 - U
 - V
 - W
 - X
 - Y
 - Z
- 1
 - 2
 - 3
 - 4
 - 5
 - 6
 - 7
 - 8
 - 9

Trending Now

- | | |
|-------------------------------|-------------------|
| India Railways | Zee Entertainment |
| Vodafone Idea | Air India |
| Bharat Biotech | Petrol Price |
| CIL | Jiopages |
| IRCTC News | Railways ministry |
| Indian Navy News | Netflix News |
| Ministry of Corporate Affairs | Delhi Metro |
| Reliance Jio | |

Popular Categories

- | | |
|---------------------|-----------------|
| Auto | Banking/Finance |
| Cons. Products | Energy |
| Renewables | Ind'l Goods/Svs |
| Healthcare/Biotech | Services |
| Media/Entertainment | Transportation |
| Tech | Telecom |
| Miscellaneous | CSR |
| Environment | |

Hot On Web

- | | |
|-----------------------------------|--------------------------------|
| Aryan Khan Drug Case LIVE Updates | Sensex today |
| Cryptocurrency | Mutual funds SIP 2021 |
| What are multi asset funds | What are balanced mutual funds |
| Global markets | Mutual funds |
| Breaking news | LTC Cash Voucher Scheme |
| SGX Nifty | Sensex Live |
| IRCTC share price | Infosys share price |
| Rupee | Aadhaar Card |
| How to save Income Tax | |

In Case You Missed It

- | | |
|----------------|--------------------|
| India Railways | Punit Goenka |
| IMF | CIL |
| Vodafone Idea | Air India |
| Bharat Biotech | Petrol Price Today |
| Jiopages | AGR dues |
| Auto News | Banking News |
| Jio Fiber | |

ET Verticals

- | | |
|------------------|------------------------------|
| Auto News | Retail News |
| Health News | Telecom News |
| Energy News | IT News |
| Real Estate News | Marketing & Advertising News |
| Technology News | CFO News |
| IT Security News | |

More From Our Network

- | | | |
|-----------------------|------------------|------------------------|
| Pune Mirror | Bangalore Mirror | Ahmedabad Mirror |
| ItsMyAscent | Education Times | Brand Capital |
| Mumbai Mirror | Times Now | Indiatimes |
| महाराष्ट्र टाइम्स | ವಿಜಯ ಕರ್ನಾಟಕ | Go Green |
| AdAge India | Eisamay | IGN India |
| IamGujarat | Times of India | Samayam Tamil |
| Samayam Telugu | Miss Kyra | Bombay Times |
| Filmipop | MX Player | Newspaper Subscription |
| Times Prime | Colombia | NBT Gold Podcast |
| Ei Samay Gold Podcast | MX ShareKaro App | MX TakaTak App |

Nifty **CLOSED**
18338.55 176.80

Other Useful Links

- About Us
- Book your Newspaper Subscription
- Advertise with Us
- Privacy policy
- RSS
- Subscribe to ET Prime
- Create Your Own Ad
- Terms of Use & Grievance Redressal
- Contact Us
- DNPA Code of Ethics

Services

- Longwalks App

Follow Us On:

Download ET App:

SUBSCRIBE TO
OUR
NEWSLETTER

Copyright © 2021 Bennett, Coleman & Co. Ltd. All rights reserved. For reprint rights: [Times Syndication Service](#)

Nifty **CLOSED**
18338.55 176.80